Hence, it is postulated that the potential mechanism underlying the therapeutic effects of AR in the treatment of T2DM involves the activation of the RAGE protein, subsequently modulating the pivotal PI3K/Akt pathway associated with renal injury (see Figure 10). Here, AKT1 is linked to type 2 diabetes mellitus.